1-17 of 17
Brad Kahl, MD
Close
Sort by
Articles

Chronic Lymphocytic Leukemia and a Pandemic: A Bad Combination

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2022) 19 (1)
https://doi.org/10.1182/hem.V19.1.202212
Published: 2022
Articles

Major Advances in Hairy Cell Leukemia

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2021) 18 (6)
https://doi.org/10.1182/hem.V18.6.202165
Published: 2021
Articles

Moving Beyond CHO(E)P for Peripheral T-cell Lymphoma

Neha Mehta-Shah, MD, Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2021) 18 (5)
https://doi.org/10.1182/hem.V18.5.202155
Published: 2021
Articles

A Prognostic Index for Burkitt Lymphoma

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2021) 18 (4)
https://doi.org/10.1182/hem.V18.4.202146
Published: 2021
Articles

Ibrutinib for the Treatment of Waldenström Macroglobulinemia: Some Mutations Are Better Than Others

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2021) 18 (3)
Published: 2021
Articles

A Predictive Biomarker in Lymphoma: Better Late Than Never

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2021) 18 (2)
Published: 2021
Articles

A New CAR-T Option for Mantle Cell Lymphoma

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2020) 18 (1)
Published: 2020
Articles

Is Dose-adjusted EPOCH-R Enough in Burkitt Lymphoma?

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2020) 17 (6)
Published: 2020
Articles

S1826: U.S. Intergroup Trial for Advanced-Stage Hodgkin Lymphoma

Alex F. Herrera, MD, Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2020) 17 (5)
Published: 2020
Articles

Are We Capable of Curing Follicular Lymphoma, But Just Afraid to Say It?

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2020) 17 (3)
https://doi.org/10.1182/hem.V17.3.10369
Published: 2020
Articles

Picking a Partner: As in Life, it Matters for MYC

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2020) 17 (2)
https://doi.org/10.1182/hem.V17.2.10279
Published: 2020
Articles

Frontline CLL Options: An Embarrassment of Riches?

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2019) 17 (1)
https://doi.org/10.1182/hem.V17.1.10148
Published: 2019
Articles

RIP FCR?

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2019) 16 (6)
https://doi.org/10.1182/hem.V16.6.9931
Published: 2019
Articles

Is It Time for Time-limited Therapy in Frontline CLL?

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2019) 16 (5)
https://doi.org/10.1182/hem.V16.5.9796
Published: 2019
Articles

Is Double-hit Diffuse Large B-cell Lymphoma More Common Than We Think?

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2019) 16 (4)
https://doi.org/10.1182/hem.V16.4.9652
Published: 2019
Articles

Can We Use MRD Status to Personalize Therapy in Mantle Cell Lymphoma?

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2019) 16 (3)
https://doi.org/10.1182/hem.V16.3.9575
Published: 2019
Articles

Keeping Your ESCHELONs Straight

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2019) 16 (2)
https://doi.org/10.1182/hem.V16.2.9387
Published: 2019